The significance of lipid peroxidation in cardiovascular disease

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 442, Issue , 2014, Pages 173-180

  Siegel, Günter ^a,b   Ermilov, Eugeny ^a   Pries, Axel R ^a   Winkler, Karl ^c   Schmidt, Annette ^d   Ringstad, Lovisa ^e   Malmsten, Martin ^a,b   Lindman, Björn ^f,g  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e INSTITUTE FOR SURFACE CHEMISTRY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Biomarkers; Clinical trial; Ellipsometry; Ginkgo biloba; Metabolic syndrome; Personalized medicine

Indexed keywords

BIOMARKERS; BLOOD PRESSURE; ELLIPSOMETRY; EXPERIMENTS; FLUORESCENCE MICROSCOPY; LIPIDS; METABOLISM; NUTRITION; OXIDATIVE STRESS; PATIENT MONITORING; PLASMA DIAGNOSTICS;

CARDIO-VASCULAR RISK FACTORS; CHILDREN AND ADOLESCENTS; CLINICAL TRIAL; GINKGO BILOBA; HIGH-DENSITY LIPOPROTEINS; METABOLIC SYNDROMES; OXIDATIVE STRESS BIOMARKERS; PERSONALIZED MEDICINES;

DIAGNOSIS;

8 ISOPROSTAGLANDIN F2 ALPHA; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; CYCLIC AMP; CYCLIC GMP; GELATINASE B; GINKGO BILOBA EXTRACT; INSULIN; INTERLEUKIN 6; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; ROKAN NOVO; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; URIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTERIOSCLEROSIS; ARTICLE; BIOSENSOR; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MONITORING; ELLIPSOMETRY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OXIDATIVE STRESS; PERSONALIZED MEDICINE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOMETRY; PRIORITY JOURNAL; PROCEDURES; PROSTAGLANDIN BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL;

EID: 84895064504     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2013.05.022     Document Type: Article

References (52)

1. Siegel G., Ermilov E., Saunders R., Pries A.R., Malmsten M. Nanotechnologic point-of-care ellipsometric device for arteriosclerotic diseases. Arterioscler. Thromb. Vasc. Biol. 2010, 30:e210.
2. Siegel G., Malmsten M., Klüßendorf D., Leonhardt W. Physicochemical binding properties of the proteoglycan receptor for serum lipoproteins. Atherosclerosis 1999, 144:59-67.
3. Abletshauser C., Klüßendorf D., Schmidt A., Winkler K., März W., Buddecke E., Malmsten M., Siegel G. Biosensing of arteriosclerotic nanoplaque formation and interaction with an HMG-CoA reductase inhibitor. Acta Physiol. Scand. 2002, 176:131-145.
4. Siegel G., Abletshauser C., Malmsten M., Schmidt A., Winkler K. Reduction of arteriosclerotic nanoplaque formation and size by fluvastatin in a receptor-based biosensor model. Cardiovasc. Res. 2003, 58:696-705.
5. Siegel G., Rodríguez M., Sauer F., Abletshauser C., de Mey C., Schötz K., Ringstad L., Malmsten M., Schäfer P. Nanotechnologic biosensor ellipsometry and biomarker pattern analysis in the evaluation of atherosclerotic risk profile. Biosens. Bioelectron. 2009, 24:1512-1517.
6. Siegel G., Schmidt A., Schäfer P., Malmsten M., Ringstad L., Winkler K., Just S. The importance of scavenging reactive oxygen species in anti-aging medicine. Eng. Life Sci. 2009, 9:363-375.
7. Siegel G., Overbeck B., Malmsten M., Winkler K., Ermilov E. Biomarker pattern analysis and tolerability of Ginkgo biloba (EGb 761) in point-of-care theranostics of metabolic syndrome patients. Diabetes 2011, 60(Suppl. 1):A626.
8. Siegel G., Overbeck B., Just S., Winkler K., Malmsten M., Ermilov E. Alkaline phosphatase lowering in metabolic syndrome patients utilizing a phytochemical approach. Am. J. Gastroenterol. 2011, 106(Suppl. 2):S130.
9. Siegel G., Winkler K., Lubitz I., Ermilov E. Multiparametric biomarkers as determinants of insulin resistance. Diabetes 2012, 61(Suppl. 1):A627.
10. Rodríguez M., Ringstad L., Schäfer P., Just S., Hofer H.W., Malmsten M., Siegel G. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis 2007, 192:438-444.
11. Siegel G., Ermilov E. Omega-3 fatty acids: benefits for cardio-cerebro-vascular diseases. Atherosclerosis 2012, 225:291-295.
12. Siegel G., Ermilov E., Hammersen S., Elmen G. In vitro effect of blackcurrant anthocyanins on flow-dependent dilatation of human intracerebral arteries and Alzheimer nanoplaque formation. Circulation 2012, 125(10 Suppl.):AP356.
13. Siegel G., Malmsten M. Molecular model for athero/arteriosclerosis, patent EP 0 946 876 2005.
14. Malmsten M., Burns N., Veide A. Electrostatic and hydrophobic effects of oligopeptide insertions on protein adsorption. J. Colloid Interface Sci. 1998, 204:104-111.
15. Malmsten M., Claesson P., Siegel G. Forces between proteoheparan sulfate layers adsorbed at hydrophobic surfaces. Langmuir 1994, 10:1274-1280.
16. Malmsten M., Siegel G., Becker A. A model substrate for ellipsometry studies of lipoprotein deposition at the endothelium. J. Colloid Interface Sci. 2001, 240:372-374.
17. Siegel G., Ermilov E. Hs-CRP may be associated with white blood cell count in metabolic syndrome patients treated with Ginkgo biloba. Atherosclerosis 2011, 218:250-252.
18. De Feijter J.A., Benjamins J., Veer F.A. Ellipsometry as a tool to study the adsorption behavior of synthetic and biopolymers at the air-water interface. Biopolymers 1978, 17:1759-1772.
19. Alberti K.G.M.M., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, Provisional report of a WHO consultation. Diabet. Med. 1998, 15:539-553.
20. Grundy S.M., Becker D., Clark L.T., Cooper R.S., Denke M.A., Howard W.J., Hunninghake D.B., Illingworth D.R., Luepker R.V., McBride P., McKenney J.M., Pasternak R.C., Stone N.J., Van Horn L. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
21. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
22. Alberti K.G.M.M., Zimmet P., Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005, 366:1059-1062. for the IDF Epidemiology Task Force Consensus Group.
23. Schäfer P., Rodríguez M., Siegel G., Atherosclerosis an inflammatory and fibroproliferative disease. A prophylactic phytochemical approach with Ginkgo biloba (EGb 761). Atherosclerosis 2007, 195:419-422.
24. Hoffmann C.J., Hohberg M., Chlench S., Maroski J., Drab M., Siegel G., Pries A.R., Zakrzewicz A. Suppression of zinc finger protein 580 by high oxLDL/LDL-ratios is followed by enhanced expression of endothelial IL-8. Atherosclerosis 2011, 216:103-108.
25. Vassalle C., Botto N., Andreassi M.G., Berti S., Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron. Artery Dis. 2003, 14:213-218.
26. Weiss S.J. Tissue destruction by neutrophils. N. Engl. J. Med. 1989, 320:365-376.
27. Klebanoff S.J. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 2005, 77:598-625.
28. Nomoto K., Oguchi S., Watanabe I., Kushiro T., Kanmatsuse K. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. J. Cardiol. 2003, 42:201-206.
29. Lusis A.J., Fogelman A.M., Fonarow G.C. Genetic basis of atherosclerosis: Part II: clinical implications. Circulation 2004, 110:2066-2071.
30. Kameda K., Matsunaga T., Abe N., Hanada H., Ishizaka H., Ono H., Saitoh M., Fukui K., Fukuda I., Osanai T., Okumura K. Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur. Heart J. 2003, 24:2180-2185.
31. Baldus S., Eiserich J.P., Mani A., Castro L., Figueroa M., Chumley P., Ma W., Tousson A., White C.R., Bullard D.C., Brennan M.-L., Lusis A.J., Moore K.P., Freeman B.A. Endothelial transcytosis of myeloperoxidase confers specificity to vascular ECM proteins as targets of tyrosine nitration. J. Clin. Invest. 2001, 108:1759-1770.
32. Kong Y.-Z., Yu X., Tang J.-J., Ouyang X., Huang X.-R., Fingerle-Rowson G., Bacher M., Scher L.A., Bucala R., Lan H.Y. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis 2005, 178:207-215.
33. Anber V., Millar J.S., McConnell M., Shepherd J., Packard C.J. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2507-2514.
34. Camejo G., Hurt-Camejo E., Wiklund O., Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998, 139:205-222.
35. Davignon J., Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004, 109:III-27-III-32.
36. Silaste M.-L., Rantala M., Alfthan G., Aro A., Witztum J.L., Kesäniemi Y.A., Hörkkö S. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler. Thromb. Vasc. Biol. 2004, 24:498-503.
37. Tsimikas S. In vivo markers of oxidative stress and therapeutic interventions. Am. J. Cardiol. 2008, 101:34D-42D.
38. el Hafny B., Bourre J.-M., Roux F. Synergistic stimulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities by retinoic acid and astroglial factors in immortalized rat brain microvessel endothelial cells. J. Cell. Physiol. 1996, 167:451-460.
39. Glorioso N., Troffa C., Filigheddu F., Dettori F., Soro A., Pinna Parpaglia P., Collatina S., Pahor M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34:1281-1286.
40. Spósito A.C., Mansur A.P., Coelho O.R., Nicolau J.C., Ramires J.A. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am. J. Cardiol. 1999, 83:1497-1499.
41. Borghi C., Prandin M.G., Costa F.V., Bacchelli S., Degli Esposti D., Ambrosioni E. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 2000, 35:549-555.
42. Ichihara A., Hayashi M., Koura Y., Tada Y., Kaneshiro Y., Saruta T. Long-term effects of statins on arterial pressure and stiffness of hypertensives. J. Hum. Hypertens. 2005, 19:103-109.
43. Kaesemeyer W.H., Caldwell R.B., Huang J., Caldwell R.W. Pravastin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. JACC 1999, 33:234-241.
44. Nickenig G., Bäumer A.T., Temur Y., Kebben D., Jockenhövel F., Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999, 100:2131-2134.
45. Wassmann S., Laufs U., Bäumer A.T., Müller K., Ahlbory K., Linz W., Itter G., Rösen R., Böhm M., Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37:1450-1457.
46. Glass C.K., Witztum J.L. Atherosclerosis: The road ahead. Cell 2001, 104:503-516.
47. Ridker P.M. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit. Am. Heart J. 2004, 148:S19-S26.
48. Libby P. Inflammation in atherosclerosis. Nature 2002, 420:868-874.
49. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
50. Hansson G.K., Inflammation atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
51. Gorelick P.B., Wong K.S., Bae H.-J., Pandey D.K. Large artery intracranial occlusive disease. A large worldwide burden but a relatively neglected frontier. Stroke 2008, 39:2396-2399.
52. Siegel G., Jumar A., de Mey C., Ermilov E. Pleiotropic effects of Ginkgo biloba: implication in blood pressure regulation. Hypertension 2012, 60:A301.